BUZZ-Morningstar sees margin expansion at Australia's Telix Pharmaceuticals, maintains revenue outlook

Telix
Morningstar
TRANS-LUX CORP

Telix

TLX

0.00

Morningstar

MORN

0.00

TRANS-LUX CORP

TNLX

0.00

** Morningstar expects Telix Pharmaceuticals' TLX.AX EBIT margins to expand by 29% by midcycle

** TLX on Tuesday posted quarterly group revenue of $230 million, reiterated 2026 revenue forecast of $950 million-$970 million

** "Telix is on track to meet our 2026 revenue forecast of USD 960 million, which we leave unchanged," Morningstar says

** Growth in core prostate cancer imaging continues to underpin TLX's performance, the investor research firm says

** Morningstar expects momentum to persist alongside a successful 2026 launch of TLX's pipeline product Pixclara, an investigational agent for imaging glioma

** Morningstar maintains A$18 fair value estimate for TLX

** All 13 analysts rate the stock "buy" or higher; their median PT is A$23.15 – LSEG data

** YTD, TLX up 21.3% as of last close


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.